查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1418428

血管舒縮症狀市場報告：2030 年趨勢、預測與競爭分析

Vasomotor Symptoms Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血管舒縮症狀的趨勢和預測

預計 2024 年至 2030 年，全球血管舒縮症狀市場將以 5.8% 的年複合成長率成長。該市場的主要驅動力是由於久坐的生活方式、遺傳、荷爾蒙波動和不良飲食導致血管舒縮症狀頻率上升，以及資助研發和潛在臨床試驗的公司。參與企業數量正在增加。全球血管舒縮症狀市場的未來充滿希望，醫院、診所和專科中心市場充滿機會。

血管舒縮症狀市場洞察

Lucintel 預測，在預測期內，聯合治療將繼續成為有效治療血管舒縮症狀的較大部分。

在這個市場中，在治療血管舒縮疾病方面擁有豐富專業知識的專科中心將繼續佔據很大一部分。

由於更年期疾病的高盛行率，在預測期內，北美將繼續成為最大的地區。

常問問題

Q1.市場成長預測如何？

A1. 2024年至2030年，全球血管舒縮症狀市場預計將以5.8%的年複合成長率成長。

Q2.影響市場成長的主要促進因素有哪些？

A2. 該市場的主要促進因素是久坐的生活方式、遺傳、荷爾蒙波動和不良飲食導致血管舒縮症狀頻率增加，以及資助研發和潛在臨床試驗的公司。參與企業數量正在增加。

Q3.市場的主要細分市場有哪些？

A3. 血管舒縮症狀市場的未來看起來充滿希望，醫院/診所和專科中心市場存在機會。

Q4.市場上主要企業有哪些？

A4. 治療血管舒縮症狀的主要企業如下。

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計，在有效治療血管舒縮症狀的預測期內，聯合治療仍將佔據較大佔有率。

Q6. 未來五年預計哪個地區的市場最大？

A6. 由於北美地區更年期盛行率較高，因此在預測期內北美將繼續成為最大的地區。

Q7. 可以客製化報告嗎？

A7. 是的，Lucintel 提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球血管舒縮症狀市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球血管舒縮症狀市場趨勢（2018-2023）與預測（2024-2030）
  • 全球血管舒縮症狀市場：依治療方法
    • 雌激素
    • 黃體酮
    • 組合
    • 市售荷爾蒙
    • 抗憂鬱症
    • 其他
  • 全球血管舒縮症狀市場：按分銷管道
    • 醫院藥房
    • 零售藥房
    • 藥局
  • 全球血管舒縮症狀市場：依最終用途分類
    • 醫院和診所
    • 專業中心
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球血管舒縮症狀市場（按地區）
  • 北美洲血管舒縮症狀市場
  • 歐洲血管舒縮症狀市場
  • 亞太血管舒縮症狀市場
  • 其他地區血管舒縮症狀市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球血管舒縮症狀市場的治療方法成長機會
    • 全球血管舒縮症狀市場成長機會（按分銷管道）
    • 全球血管舒縮症狀市場成長機會（依最終用途）
    • 按地區分類的全球血管舒縮症狀市場成長機會
  • 全球血管舒縮症狀市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球血管舒縮症狀市場容量擴張
    • 全球血管舒縮症狀市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter and Gamble
  • TherapeuticsMD
  • Emcure Pharmaceuticals
  • Eli Lily and Company
  • Novartis
  • Novo Nordisk
  • Pfizer
簡介目錄

Vasomotor Symptoms Trends and Forecast

The future of the global vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets. The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

A more than 150-page report is developed to help in your business decisions.

Vasomotor Symptoms by Segment

The study includes a forecast for the global vasomotor symptoms by therapy type, distribution channel, end use, and region.

Vasomotor Symptoms Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

  • Estrogen
  • Progesterone
  • Combination
  • OTC Hormone
  • Anti-Depressants
  • Others

Vasomotor Symptoms Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores

Vasomotor Symptoms Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals And Clinics
  • Specialty Centers
  • Others

Vasomotor Symptoms Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Vasomotor Symptoms Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies vasomotor symptoms companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vasomotor symptoms companies profiled in this report include-

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Vasomotor Symptoms Market Insights

Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Within this market, specialty centers will remain the larger segment due to more expertise in treating vasomotor symptoms.

North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Features of the Global Vasomotor Symptoms Market

Market Size Estimates: Vasomotor symptoms market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Vasomotor symptoms market size by therapy type, distribution channel, end use, and region in terms of value ($B).

Regional Analysis: Vasomotor symptoms market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy type, distribution channel, end use, and regions for the vasomotor symptoms market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the vasomotor symptoms market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for vasomotor symptoms market?

Answer: The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the vasomotor symptoms market?

Answer: The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

Q3. What are the major segments for vasomotor symptoms market?

Answer: The future of the vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets.

Q4. Who are the key vasomotor symptoms market companies?

Answer: Some of the key vasomotor symptoms companies are as follows.

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Q5. Which vasomotor symptoms market segment will be the largest in future?

Answer: Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Q6. In vasomotor symptoms market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the vasomotor symptoms market by therapy type (estrogen, progesterone, combination, OTC hormone, anti-depressants, and others), distribution channel (hospital pharmacy, retail pharmacy, and drug stores), end use (hospitals and clinics, specialty centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Vasomotor Symptoms Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Vasomotor Symptoms Market by Therapy Type
    • 3.3.1: Estrogen
    • 3.3.2: Progesterone
    • 3.3.3: Combination
    • 3.3.4: OTC Hormone
    • 3.3.5: Anti-Depressants
    • 3.3.6: Others
  • 3.4: Global Vasomotor Symptoms Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Drug Stores
  • 3.5: Global Vasomotor Symptoms Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Specialty Centers
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Vasomotor Symptoms Market by Region
  • 4.2: North American Vasomotor Symptoms Market
    • 4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.3: European Vasomotor Symptoms Market
    • 4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.4: APAC Vasomotor Symptoms Market
    • 4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.5: ROW Vasomotor Symptoms Market
    • 4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
    • 6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
    • 6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
  • 6.2: Emerging Trends in the Global Vasomotor Symptoms Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceuticals
  • 7.2: Merck
  • 7.3: Mithra Pharmaceuticals
  • 7.4: Procter and Gamble
  • 7.5: TherapeuticsMD
  • 7.6: Emcure Pharmaceuticals
  • 7.7: Eli Lily and Company
  • 7.8: Novartis
  • 7.9: Novo Nordisk
  • 7.10: Pfizer